Silo Pharma, Inc. — Form 8-K Summary
Business context and reporting period
The 8-K reports an asset purchase agreement entered into on October 1, 2026, between Silo Pharma, Inc. and Norsight Consulting Inc. Silo agreed to acquire software, technology and related intellectual property, including trademarks, domain names, data and trade secrets. The filing reports a transaction, not a quarterly or annual financial results period.
Transaction terms and key metrics
- As consideration, Silo issued Norsight a warrant to purchase up to 300,000 shares of Silo common stock at $1.51 per share.
- The warrant is exercisable beginning April 1, 2027, and expires September 30, 2031. It includes a cashless exercise feature.
- Exercise is subject to a 4.99% beneficial ownership limit, which may be increased up to 9.99%; an increase requires at least 61 days’ prior notice to Silo.
- Shares received in connection with the agreement, including warrant shares, are subject to a lock-up ending at the earliest of 12 months after the agreement date, a defined change in control, or Silo’s written consent.
- The filing text does not provide a clear cash purchase price or valuation for the acquired assets.
Financial results and changes
The filing does not report revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics. It provides no comparable-period financial results. The transaction may result in the issuance of up to 300,000 shares upon warrant exercise; actual issuance depends on exercise and the warrant’s terms.
Outlook, risks and unusual items
No financial guidance or business outlook is provided. The agreement includes customary representations, warranties and covenants. Norsight agreed to indemnify Silo for specified breaches or misrepresentations, third-party rights infringement involving the purchased assets, and Norsight’s gross negligence, fraud or intentional misconduct. The warrant was offered and sold in reliance on the Securities Act exemption under Section 4(a)(2).
Important facts for investors to verify
- Review the full asset purchase agreement and warrant, filed as Exhibits 10.1 and 4.1, for the complete terms, asset details, and any conditions or limitations.
- Verify the acquired assets’ scope, valuation and expected contribution to Silo’s business; the 8-K summary does not quantify these items.
- Monitor potential dilution, warrant exercise timing and price, cashless exercise provisions, ownership limits, and the lock-up provisions.
- Review any omitted agreement schedules if they become available; the filing states that schedules were omitted and may be furnished to the SEC upon request.